OncoSec inks deal with Merck to study drug-device therapy for metastatic melanoma

OncoSec Medical (NSDQ:ONCS) said today that it inked a clinical trial collaboration and supply agreement with Merck (NYSE:MRK) to evaluate the combination of its ImmunoPulse IL-12 electroporation device with Merck’s Keytruda therapy in a Phase II clinical trial. The trial aims to evaluate the drug-device combination in patients with metastatic melanoma – specifically patients who experienced disease progression after previous treatment with an anti-PD-1 therapy. OncoSec’s electroporation device delivers a sequence of short-duration electrical pulses to increase the cancer cell membrane’s permeability and more efficiently deliver cancer-killing drugs. Get the full story at our sister site, Drug Delivery Business News. The post OncoSec inks deal with Merck to study drug-device therapy for metastatic melanoma appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Biotech Clinical Trials Drug-Device Combinations Oncology Pharmaceuticals Wall Street Beat OncoSec Medical Source Type: news